Bausch Health Companies Inc. filings document regulatory disclosures for a global diversified pharmaceutical company incorporated in British Columbia. The record includes Form 8-K reports for quarterly and annual operating results, Regulation FD updates, clinical-program disclosures, material agreements, debt exchanges and credit-agreement refinancing involving Bausch Health and its subsidiaries, including Bausch + Lomb.
Proxy materials describe annual meeting matters, director elections, auditor approval, executive compensation votes and governance procedures. Other current reports address compensatory arrangements, including performance share unit settlement terms, and capital-structure disclosures tied to senior secured notes, guarantees, collateral arrangements and refinancing transactions.
LEE STEVEN HYOSIG reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. reported that senior vice president, controller and chief accounting officer Steven Hyosig Lee received an equity grant in the form of restricted share units. He was awarded 45,868 common share RSUs at no purchase price, which will vest in three equal annual installments.
These units vest one-third on each of the first three anniversaries of the grant date, conditional on his continued service. Once vested, each RSU will be settled in one common share of Bausch Health. Following this grant, his directly held common shares total 73,239.
Bausch Health Companies Inc. executive Aimee J. Lenar reported equity compensation changes in company common shares. She received a grant of 157,139 restricted share units at $0.0000 per share on February 25, 2026, increasing her direct holdings to 417,913 shares.
These RSUs vest one-third on each of the first three anniversaries of the grant date, contingent on continued service, and are settled in common shares. On February 26, 2026, 17,578 common shares valued at $6.04 per share were withheld to cover tax obligations upon RSU vesting, leaving her with 400,335 directly held shares.
Bausch Health Companies Inc. executive vice president and general counsel Seana Carson reported several equity transactions in company common shares. Carson received an award of 212,350 restricted share units (RSUs), which will vest in three equal annual installments, with vested RSUs settled in common shares.
To cover tax withholding on a prior RSU vesting, 32,211 common shares were withheld and disposed of at $6.04 per share. Carson also completed an open-market sale of 8,388 common shares at $5.95 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on May 7, 2025. After these transactions, Carson directly holds 809,258 common shares of Bausch Health.
Bausch Health Companies Inc. EVP and CFO Jean-Jacques Charhon reported equity compensation and related tax withholding in this insider filing. On February 25, 2026, he acquired 276,055 restricted share units (RSUs) for no cash consideration. These RSUs vest one-third on each of the first three anniversaries of the grant date, and vested RSUs are settled in Bausch Health common shares.
On February 26, 2026, 35,977 common shares were disposed of at $6.04 per share to satisfy tax withholding obligations upon RSU vesting, rather than as an open-market sale. After these transactions, Charhon directly held 755,538 common shares of Bausch Health.
Bausch Health Companies Inc. director and Chief Executive Officer Thomas Appio reported two equity compensation transactions involving the company’s common shares.
On February 25, 2026, he acquired 815,425 common shares at $0.00 per share as a grant of restricted share units (RSUs). According to the filing, these RSUs vest in three equal annual installments over three years and are settled in common shares upon vesting.
On February 26, 2026, 116,502 common shares were disposed of in a tax-withholding transaction at $6.04 per share to cover obligations arising from RSU vesting, rather than an open-market sale. Following these transactions, Appio directly owned 3,620,034 common shares.
Bausch Health Companies Inc. filed its annual report describing a diversified global portfolio in gastroenterology, dermatology, neurology, international pharma and eye health. 2025 revenues were $10,266 million, up from $9,625 million in 2024 and $8,757 million in 2023, reflecting multi‑year growth.
The company’s key U.S. GI brand Xifaxan generated $2,212 million of 2025 revenue and faces future U.S. Medicare price cuts after negotiation under the Inflation Reduction Act starting in 2027, ahead of anticipated generic competition from 2028. Bausch Health also acquired DURECT Corporation, adding Larsucosterol, an FDA Breakthrough Therapy for alcohol‑associated hepatitis.
Bausch Health continues to pursue the planned separation of its majority‑owned eye‑care subsidiary Bausch + Lomb, in which it holds about 88% of the common shares as of February 11, 2026. Completion of this separation depends on leverage targets, approvals and ongoing Xifaxan litigation. The report details extensive regulatory, pricing, competition and compliance risks affecting its global operations.
Bausch Health Companies Inc. reported solid 2025 growth with some mixed bottom-line items. Fourth-quarter revenue was $2.80 billion, up 9% reported and 6% organically, while full-year revenue reached $10.27 billion, up 7% reported and 5% organically versus 2024.
Full-year GAAP net income attributable to Bausch Health was $157 million, reversing a prior-year loss, but the company posted a fourth-quarter GAAP net loss of $112 million driven by a $145 million goodwill impairment in its Generics unit and a $112 million deferred tax asset valuation allowance. Adjusted net income attributable to Bausch Health was $411 million for the quarter and $1.40 billion for the year, while adjusted EBITDA attributable to Bausch Health rose to $1.05 billion in Q4 and $3.54 billion for 2025.
The company generated $1.40 billion of operating cash flow in 2025, down from $1.60 billion, mainly due to higher working capital and interest payments. Management highlighted 11 consecutive quarters of revenue and adjusted EBITDA growth excluding Bausch + Lomb, the acquisition of Shibo’s aesthetics distribution business in China, and $9.6 billion of 2025 refinancing, including extending $1.6 billion of debt maturities to 2032. For 2026, Bausch Health guides to total revenue of $10.625–$10.875 billion and adjusted EBITDA of $3.875–$4.000 billion, with Bausch Health excluding Bausch + Lomb targeting $1.200–$1.275 billion in adjusted operating cash flow.
Bausch Health Companies Inc. reported that Chief Executive Officer and director Thomas Appio acquired 1,137,862 Common Shares at a price of $0 through a grant or award tied to performance-based restricted share units (PSUs). These PSUs were earned on February 9, 2026 after the board committee certified financial performance for the period from January 1, 2023 through December 31, 2025. The units remain subject to a service-based vesting condition through March 2, 2026, after which the earned Common Shares will be delivered. Following this award, Appio beneficially owns 2,921,111 Common Shares directly.
Bausch Health Companies EVP and General Counsel Seana Carson reported an acquisition of 137,922 common shares on February 9, 2026 through a performance-based equity award. These shares relate to performance-based restricted share units originally granted on March 2, 2023.
On February 9, 2026, the Talent and Compensation Committee certified financial performance metrics for the period from January 1, 2023 through December 31, 2025, causing the PSUs to be earned. The units remain subject to service-based vesting through March 2, 2026, after which the company will deliver the earned common shares, bringing Carson’s direct beneficial ownership to 637,507 shares.